Search hospitals > Louisiana > Shreveport
Louisiana State University Health Sciences Center Shreveport
Claim this profileShreveport, Louisiana 71103
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Lymphoma
Conducts research for Leukemia
312 reported clinical trials
11 medical researchers
Summary
Louisiana State University Health Sciences Center Shreveport is a medical facility located in Shreveport, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Leukemia and other specialties. Louisiana State University Health Sciences Center Shreveport is involved with conducting 312 clinical trials across 425 conditions. There are 11 research doctors associated with this hospital, such as Gary V. Burton, Samip Master, Poornima Ramadas, and Kavitha Beedupalli.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Gary V. BurtonLSU Health Sciences Center at Shreveport1 year of reported clinical research
Expert in Breast Cancer
Studies Cancer
22 reported clinical trials
40 drugs studied
Samip MasterLSU Health Sciences Center at Shreveport3 years of reported clinical research
Studies Plasma Cell Neoplasms
Studies Multiple Myeloma
5 reported clinical trials
13 drugs studied
Poornima RamadasLSU Health Sciences Center at Shreveport4 years of reported clinical research
Studies Lymphoma
Studies Leukemia
4 reported clinical trials
14 drugs studied
Kavitha BeedupalliOchsner LSU Health Monroe Medical Center9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
4 reported clinical trials
7 drugs studied
Clinical Trials running at Louisiana State University Health Sciences Center Shreveport
Breast Cancer
Diffuse Large B-Cell Lymphoma
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Cancer
Lung Cancer
Lymphoma
Pancreatic Cancer
Plasma Cell Neoplasms
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Louisiana State University Health Sciences Center Shreveport?
Louisiana State University Health Sciences Center Shreveport is a medical facility located in Shreveport, Louisiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Lymphoma, Leukemia and other specialties. Louisiana State University Health Sciences Center Shreveport is involved with conducting 312 clinical trials across 425 conditions. There are 11 research doctors associated with this hospital, such as Gary V. Burton, Samip Master, Poornima Ramadas, and Kavitha Beedupalli.
Where is Louisiana State University Health Sciences Center Shreveport located?
**Louisiana State University Health Sciences Center Shreveport**
- **Address:** 1501 Kings Highway, Shreveport, LA 71103
- **Free Patient Parking:** Available at the Gordon H. Schuckers Rehabilitation Pavilion, 1450 Claiborne Ave, Shreveport, LA 71103.
Who should I call to ask about financial aid or insurance network?
**Louisiana State University Health Sciences Center Shreveport - Financial and Insurance Assistance**
- For financial assistance, reach out to the Office of Financial Aid at LSUS.
- For insurance-related inquiries, contact the Registrar's office at registrar@lsuhs.edu or call 318-675-5207.
What insurance does Louisiana State University Health Sciences Center Shreveport accept?
The Louisiana State University Health Sciences Center Shreveport accepts a wide range of insurance plans, including:
- LSU First Health Plan
- LSU First Medicare Retiree Plan
- Blue Cross Blue Shield Magnolia Local and Local Plus
- Blue Cross Blue Shield of LA Magnolia Open Access
- Pelican HRA 1000
- Retiree Medicare Advantage plans
- Medicare Advantage Plans: LSU First Medicare Retiree Plan (United Healthcare), People's Health, Humana Blue Advantage, and Via Benefits.
What awards or recognition has Louisiana State University Health Sciences Center Shreveport received?
Louisiana State University Health Sciences Center Shreveport (LSUHS) is celebrated for the accomplishments of 14 researchers, highlighting its dedication to medical advancement. LSUHS has partnered with Digital Science to enhance its research program, striving for global recognition in both basic science and clinical research.